Moderna (NASDAQ: MRNA)
$25.09
(-2.5%)
-$0.64
Price as of April 4, 2025, 3:58 p.m. ET
MRNA
Key Data Points
Current Price
$25.09
Daily Change
(-2.5%) -$0.64
Day's Range
$23.77 - $25.76
Previous Close
$25.11
Open
$25.20
Beta
1.11
Volume
16,052,986
Average Volume
11,942,885
Sector
Market Cap
$10B
Market Cap / Employee
$2M
52wk Range
$23.76 - $170.47
Revenue
$3B
Gross Margin
48.92%
Dividend Yield
N/A
EPS
-$9.28
CAPs Rating
-
Industry
Biotechnology
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Moderna Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Moderna Company Info
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA).
News & Analysis
The Fool has written over 1,300 articles on Moderna.
Featured Article
FDA News Just Shook Moderna. Is the Stock One to Avoid or a Bad-News Buy?
Adria Cimino | Apr 3, 2025
Featured Article
Why Moderna Stock Is Plummeting Today
Johnny Rice | Mar 31, 2025
2 No-Brainer Biotech Stocks to Buy Right Now
Adria Cimino | Mar 19, 2025
4 Things You Need to Know if You Buy Moderna Stock Today
Dan Victor | Mar 18, 2025
Down 93%, Is It Finally Time to Buy Moderna?
Cory Renauer | Mar 15, 2025
Why Moderna Stock Zoomed Nearly 16% Higher on Wednesday
Eric Volkman | Mar 5, 2025
Coatue's Philippe Laffont Just Bought Shares of This Beaten-Down Growth Stock That Wall Street Predicts Will Soar 80%
Adria Cimino | Mar 4, 2025
Can Moderna's Aggressive Cost Cuts Help Turn Things Around for Its Stock?
David Jagielski | Feb 26, 2025
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Podcast Episodes

Microsoft's Gaming Ambitions and COVID-19 Stocks
Microsoft CEO Satya Nadella talked about his company's doubling down on gaming, which should give gamers and investors pause.
Chris Hill | Feb 1, 2022

Does Moderna's Coronavirus Vaccine Have an Edge?
Moderna has got some promising news on the coronavirus vaccine front.
Chris Hill | Nov 18, 2020

Why Moderna Stock Is Up
Moderna shares got a boost as the company continued its COVID-19 vaccine trials.
Chris Hill | Jul 29, 2020

Why Moderna Stock Just Went Up
Encouraging news coming out of biotech regarding its coronavirus vaccine candidate caused its stock to pop.
Chris Hill | Jul 17, 2020
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.